Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21055737 | 0.82 | ALOX5 (0.63) | PTGS2GAASMN1; SMN2ALOX5LMNA | |
| SCHEMBL11592594 | 0.81 | PTGS2 (0.66) | PTGS2GAASMN1; SMN2HTTPOLB | |
| SCHEMBL9190297 | 0.81 | GAA (0.53) | PTGS2GAASMN1; SMN2HTTPOLB | |
| SCHEMBL5444741 | 0.81 | GAA (0.68) | GAASMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL5455720 | 0.81 | GAA (0.61) | GAASMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL5446840 | 0.80 | PTGS2 (0.59) | PTGS2GAASMN1; SMN2HTTPOLB | |
| Hydrochloric Acid SCHEMBL28067312 | 0.80 | ALOX5 (0.61) | PTGS2GAASMN1; SMN2ALOX5LMNA | |
| SCHEMBL8141141 | 0.80 | POLB (0.80) | GAASMN1; SMN2HTTPOLBALDH1A1 | |
| SCHEMBL28679359 | 0.79 | ALOX5 (0.71) | PTGS2GAASMN1; SMN2HTTPOLB | |
| SCHEMBL15557417 | 0.79 | GAA (0.63) | PTGS2GAASMN1; SMN2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | disclosed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | P2RY1, P2RY4, P2RY2 | PTGS2 617/4885GAA 3492/4885SMN1; SMN2 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.